PT003/#255 Clinical outcomes with trastuzumab emtansine or ipatasertib plus paclitaxel for persistent/recurrent rare epithelial ovarian carcinomas: ENGOT-GYN2/GOG-3051/BOUQUET phase 2 biomarker-directed study

• DOI: 10.1136/ijgc-2024-igcs.26
• Publication Date: 2024-10-18T17:55:47Z
• Authors: David Gershenson; Andrés Redondo; Thibault De La Mo...; Rowan Miller; David O’malley; Sandro Pignata; Ali Ayhan; Philipp Harter; Intidhar Labidi-Galy; Beatriz Pardo; Elsa Kalbacher; Jae-Weon Kim; Charlie Gourley; Robert Coleman; Luis Manuel Manso...; Dominique Berton; Yong Man Kim; Anais Malpica; Lauren Yauch; Max Dieterich; Ophélie Caras-Zeroug; Venkatesh Krishnan; Jung-Yun Lee; Jubilee Brown; Isabelle Ray-Coquard
• Keywords: Trastuzumab emtansine; Ovarian carcinomas